Posts By Alex
506Wire StoriesTakeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis
− Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20 Response Compared...
- 545Wire Stories
Vista Gold Corp. Presenting at the 2023 Precious Metals Summit
DENVER–(BUSINESS WIRE)–Vista Gold Corp. (NYSE American and TSX: VGZ) (“Vista†or the “Companyâ€) announced today that management will hold one-on-one investor meetings...
- 500Wire Stories
Netcracker Launches Pioneering Solution to Advance Generative AI for the Telecom Industry
Netcracker GenAI Telco Solution Accelerates the Adoption of High-Value Use Cases Across the Telecom Business WALTHAM, Mass.–(BUSINESS WIRE)–Netcracker Technology announced today its...
- 539Wire Stories
Heartseed Announces the Presentation of HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure at the 71st Annual Meeting of the Japanese College of Cardiology
TOKYO–(BUSINESS WIRE)–#HS001–Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, today announced that the case reports of two...
- 506Wire Stories
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
Clinical trials will advance treatment of COVID-19 infection. BEIJING–(BUSINESS WIRE)–Sinovac Biotech Ltd. (“SINOVAC†or the “Companyâ€) (NASDAQ: SVA), a leading provider of...
- 529Wire Stories
AustralianSuper Backs Vantage Data Centers with €1.5 Billion Investment and Joins DigitalBridge as Key Shareholder
MELBOURNE, Australia & BOCA RATON, Fla. & DENVER–(BUSINESS WIRE)–AustralianSuper, Australia’s largest pension fund, today announced that it is investing €1.5 billion to...
- 562Wire Stories
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial
Daiichi Sankyo and AstraZeneca’s ENHERTU showed objective response rates of 49% and 56% with 5.4 mg/kg and 6.4 mg/kg doses, respectively, in...
- 503Wire Stories
Global Chemicals Market 2023 to 2027, Fueled by Growing Demand Across Industries – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Chemicals Market (by Category & Region): Insights & Forecast with Potential Impact of COVID-19)” report has been added to...
- 647Wire Stories
Elliptic Labs Signs PoC Contract with PC OEM, Bringing NEW Seamless and Cohesive User Experience Across the Product Lineup
OSLO, Norway–(BUSINESS WIRE)–#AI—Elliptic Labs (OSE: ELABS), a global AI software company and the world leader in AI Virtual Smart Sensorsâ„¢ currently deployed...
- 536Wire Stories
LRN Appoints New Leadership for Asia-Pacific Region
Dean Rogers to Oversee Growth After Integration of Recent Compliance Learning Acquisition from Thomson Reuters TOKYO–(BUSINESS WIRE)–LRN Corporation, the leader in ethics...
